Congressional Scrutiny Intensifies: Senator Hassan Challenges Merck Over Keytruda Patent Strategies

In a high-stakes escalation of the ongoing battle over American healthcare affordability, U.S. Senator Maggie Hassan (D-N.H.) has launched a formal inquiry into pharmaceutical giant Merck & Co., demanding accountability for the company’s aggressive patenting and pricing strategies surrounding its blockbuster cancer immunotherapy, Keytruda. As the ranking member of the Senate Finance Subcommittee on Health Care, Hassan’s latest move marks a significant intensification of congressional oversight into "patent thickets"—a strategy critics argue is specifically designed to stifle competition and keep life-saving medications at exorbitant prices for years beyond their intended patent life.

The inquiry centers on a direct letter sent to Merck CEO Robert Davis, in which Senator Hassan outlines her concerns regarding the company’s transition from the long-standing intravenous version of Keytruda to a newly launched injectable formula. By questioning the necessity and intent behind these patent maneuvers, the Senator is aiming to peel back the curtain on how pharmaceutical corporations manipulate intellectual property laws to protect lucrative monopolies at the expense of cancer patients.

The Anatomy of a Monopoly: Patent Thickets and "Product Hopping"

At the heart of the controversy is the phenomenon known as "product hopping" and the creation of "patent thickets." Pharmaceutical companies often secure a primary patent for a drug’s active ingredient. However, as that primary protection nears expiration, companies frequently file dozens, sometimes hundreds, of secondary patents for minor modifications—such as changes in delivery methods, dosing schedules, or manufacturing processes.

Keytruda, currently one of the best-selling drugs in the world, has become the poster child for this strategy. According to an extensive investigation by the International Consortium of Investigative Journalists (ICIJ) titled Cancer Calculus, Merck and its partners have filed 1,212 patent applications across 53 jurisdictions. While Merck maintains that these filings are a standard component of innovation, critics like Senator Hassan argue that they are a deliberate barrier to entry for biosimilar manufacturers.

By shifting the market toward a new injectable version of Keytruda, Merck potentially resets the clock on its exclusivity. This tactical pivot ensures that even when the primary patents for the original intravenous version expire in 2028, the company may effectively retain market dominance until the 2040s through its secondary "evergreening" patents.

Chronology of a High-Stakes Dispute

The friction between Capitol Hill and the pharmaceutical industry regarding Keytruda has been brewing for years, punctuated by several key developments:

• 2014 – Present: Keytruda gains FDA approval and rapidly becomes a cornerstone of oncology treatment for various cancers. As its efficacy is proven, its price tag consistently climbs, straining public and private insurance budgets globally.
• 2023: Merck launches its new subcutaneous (injectable) version of the drug. Investigative reports emerge suggesting this move is designed to extend market exclusivity well into the 2030s.
• Early 2024: During a Senate hearing, Senator Hassan directly challenges Merck CEO Robert Davis on the company’s anti-competitive practices. While Davis claims the system requires a balance between patent protection and market competition, his assurances fail to satisfy lawmakers.
• June 2024: The Senate Committee on Health, Education, Labor, and Pensions advances the Medication Affordability and Patent Integrity Act, a bipartisan bill sponsored by Senators Hassan and Josh Hawley (R-MO). The bill aims to reform patent review processes to prevent the abuse of the U.S. Patent and Trademark Office.
• July 2024: Senator Hassan sends her formal inquiry to Robert Davis, setting a deadline of July 20 for a detailed response regarding 10 specific questions about the company’s patent portfolio and market strategies.

Supporting Data: The Global Cost of Cancer Calculus

The economic and human impact of these pricing strategies is staggering. The Cancer Calculus investigation highlights that the cost of Keytruda is not merely a U.S. issue but a global crisis. In Germany, the annual cost of treatment exceeds $80,000; in Lebanon, it reaches $93,000; in Colombia, $130,000; and in the United States, the price can soar to a staggering $208,000 per patient per year.

These exorbitant costs have created a domino effect:

1. Counterfeit Markets: The high price of the medication has incentivized criminal syndicates to manufacture and distribute fake versions of the drug. Recent raids in Mexico uncovered counterfeit Keytruda circulating in public hospitals, posing a lethal risk to vulnerable patients.
2. Litigation: Many patients, denied access due to restrictive insurance protocols or high out-of-pocket costs, have been forced into grueling, years-long legal battles against insurers and pharmaceutical providers just to secure the treatment necessary to survive.
3. The "Evergreening" Effect: The ICIJ investigation found that these secondary patents could extend Merck’s U.S. monopoly until at least 2042. This timeline represents a 15-year delay for lower-cost biosimilars to enter the market, potentially impacting hundreds of thousands of patients who may not have the luxury of time.

Official Responses and Corporate Defenses

Merck’s stance has remained consistent throughout the scrutiny. In communications with investigative journalists and during Senate testimony, the company has characterized the assertion that they use "patent thickets" to block competition as a "common myth."

A spokesperson for Merck emphasized that the existence of multiple patents does not inherently determine when a generic or biosimilar manufacturer can enter the market. During his 2024 testimony, CEO Robert Davis argued that the current patent system is essential to incentivize the massive capital investment required for drug discovery. He explicitly stated that he would not block an intravenous biosimilar of Keytruda once the primary patents reach their expiration date.

However, Senator Hassan remains skeptical. In her letter, she pointedly noted, "Despite these statements, existing patents for [intravenous] Keytruda and a new form of the medication may help block or minimize competition from biosimilars for years." Her inquiry seeks to force transparency, specifically asking how Merck justifies the sheer volume of secondary patents and whether the shift to the injectable version is a calculated move to "hop" from one patent cycle to the next.

Implications for the Future of Drug Pricing

The inquiry into Merck is not an isolated event; it is part of a broader, systemic effort by U.S. lawmakers to address the underlying mechanics of prescription drug inflation.

The Legislative Path Forward

The Medication Affordability and Patent Integrity Act represents a critical legislative attempt to curb the influence of patent gaming. By proposing reforms to how the Patent and Trademark Office reviews drug-related filings, the bill seeks to prevent the "cluttering" of the patent system that prevents generic competitors from evaluating their entry into the market. If passed, this legislation could fundamentally alter the landscape for blockbuster biologics, potentially saving taxpayers and patients billions of dollars over the coming decades.

Market Dynamics and Patient Access

The outcome of the Hassan-Merck standoff will serve as a bellwether for the pharmaceutical industry. If the Senate succeeds in uncovering evidence of anti-competitive "product hopping," it could set a legal precedent that discourages other pharmaceutical firms from utilizing similar tactics with their own high-revenue medications. Conversely, if Merck successfully defends its patent strategy, it may embolden other firms to continue utilizing complex intellectual property filings as a primary defense against the inevitable decline of revenue that occurs when a drug loses exclusivity.

Ultimately, the debate boils down to a fundamental conflict between the incentives required for pharmaceutical innovation and the moral imperative of ensuring affordable access to life-saving healthcare. As the July 20 deadline for Merck’s response approaches, the eyes of patient advocacy groups, pharmaceutical analysts, and fellow lawmakers remain fixed on the outcome. For the patients currently relying on Keytruda, the result of this congressional inquiry could be the difference between a lifetime of financial hardship and the promise of a more affordable, competitive, and accessible future.